Bristol-Myers Squibb’s US9326945B2 Patent Under Scrutiny: Could Related Patent Weaken It?
The patent showdown between Bristol-Myers Squibb, Pfizer, and Umedica Laboratories Pvt. Ltd. has put patent US9326945B2 in the hot seat. Covering a precisely formulated version of apixaban, this patent claims
March 6, 2025
No Comments